IBM
International Business Machines Corporation
IBM has the edge over NVO overall, supported by stronger fundamentals and lower modeled downside.
NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
IBM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Under pressure |
IBM's profitability and cash flow are currently strong, and its revenue is stable, but its balance sheet is under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
IBM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $194 | -21% |
| Forward | 19x | $245 | — |
| Current | 21x | $245 | — |
| Fair | 23x | $274 | +12% |
| Expensive | 46x | $538 | +120% |
Historical ranges are pointers, not guarantees.
IBM's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 19x next year's earnings.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over IBM in the historical PE scenario, which offers more potential upside but is not a forecast.
IBM Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect IBM's earnings to grow and its profitability to improve, with its revenue holding steady.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
IBM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.06 | +11% |
| Q3 2026 | $11.75 | +40% |
| Q2 2026 | $11.29 | +83% |
| Q1 2026 | $11.33 | +94% |
| Q4 2025 | $11.17 | +74% |
| Q3 2025 | $8.38 | +22% |
| Q2 2025 | $6.18 | -32% |
| Q1 2025 | $5.83 | -34% |
| Q4 2024 | $6.43 | -21% |
IBM earned $11.75 per share over the past year, up 40% from the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
IBM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $17.1B | +4.7% |
| Q2 2026 | $17.2B | +1.1% |
| Q1 2026 | $15.9B | +9.5% |
| Q4 2025 | $19.7B | +12% |
| Q3 2025 | $16.3B | +9.1% |
| Q2 2025 | $17B | +7.7% |
| Q1 2025 | $14.5B | +0.5% |
| Q4 2024 | $17.6B | +1% |
IBM's revenue has grown year over year for 13 quarters in a row: $17.1B last quarter, up 4.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | -0.3 points |
| Q2 2026 | 14% | -0.9 points |
| Q1 2026 | 8.7% | +0.8 points |
| Q4 2025 | 21% | +2.2 points |
| Q3 2025 | 15% | +20 points |
| Q2 2025 | 15% | +1.2 points |
| Q1 2025 | 8% | +0.5 points |
| Q4 2024 | 19% | -2.8 points |
IBM's operating margin was 15% last quarter, about level with the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over IBM on profitability, with a higher operating margin.
IBM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +31% |
| Q2 2026 | $2.4B | +59% |
| Q1 2026 | $4.9B | +20% |
| Q4 2025 | $3.7B | -9.2% |
| Q3 2025 | $2.8B | +8.9% |
| Q2 2025 | $1.5B | -19% |
| Q1 2025 | $4.1B | +5% |
| Q4 2024 | $4B | -3.3% |
IBM's free cash flow has been positive every quarter for seven years: $14.7B over the past year, up 18% from the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
IBM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +260K shares |
| 1 year | +0.5% | +4.6M shares |
| 3 years | +3.2% | +29.9M shares |
| 5 years | +5.3% | +47.6M shares |
| Available history | +2.1% | +19.6M shares |
IBM has 954M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over IBM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
IBM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.9x | Elevated |
| Q2 2026 | 3.9x | Elevated |
| Q1 2026 | 4.0x | High |
| Q4 2025 | 3.5x | Elevated |
| Q3 2025 | 4.2x | High |
| Q2 2025 | 5.5x | High |
| Q1 2025 | 5.6x | High |
| Q4 2024 | 4.4x | High |
IBM's net debt is about 3.9 years of its operating earnings (EBITDA), down from 4.2 years a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over IBM on leverage, with a lower net debt burden relative to earnings.
IBM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.1 | Neutral |
| Stochastic | 74.8 | Neutral |
IBM's weekly RSI is 50 (neutral) and its Stochastic is 75 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
IBM PE vs Technology Sector
| Metric | IBM | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 31 | 35 | 4 pts below |
IBM is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over IBM on valuation relative to its sector.
IBM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $238.6 | 2.6% above |
| 20 week MA | $239.3 | 2.2% above |
| 50 week MA | $256.6 | 4.6% below |
| 100 week MA | $258.5 | 5.3% below |
| 200 week MA | $212.3 | 15% above |
IBM has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
IBM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $129.3 | $119.2 | -7.8% |
| 2021 | $119.2 | $130.6 | +9.6% |
| 2022 | $130.6 | $141.7 | +8.4% |
| 2023 | $141.7 | $163.6 | +15% |
| 2024 | $163.6 | $222.8 | +36% |
| 2025 | $222.8 | $305.1 | +37% |
| 2026 YTD | $305.1 | $244.7 | -20% |
IBM has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.